Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22447830 | 0.82 | IDO1 (0.35) | KDM4EL3MBTL1TTRGAA | |
| SCHEMBL16112511 | 0.82 | IDO1 (0.35) | KDM4EL3MBTL1TTRGAA | |
| SCHEMBL11692223 | 0.79 | — | — | |
| SCHEMBL13898991 | 0.79 | — | — | |
| SCHEMBL11691562 | 0.77 | — | — | |
| SCHEMBL8603859 | 0.70 | — | — | |
| SCHEMBL30599678 | 0.70 | — | — | |
| SCHEMBL30599677 | 0.67 | — | — | |
| SCHEMBL21582317 | 0.67 | GAA (0.32) | KDM4EL3MBTL1GAA | |
| SCHEMBL19745505 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144604-B1 | Methods for the treatment of chronic viral hepatitis C using RO 113-0830 | CONATUS PHARMACEUTICALS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| EP-2144604-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | Conatus Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008106167-A1 | COMBINATION THERAPY COMPRISING MATRIX METALLOPROTEINASE INHIBITORS AND CASPASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106166-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207569-A1 | Methods for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6268379-B1 | Substituted aryl hydroxamic acids as metalloproteinase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-1109787-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000012478-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | MMP10, MMP3, GOT2 | KDM4E 3963/4885L3MBTL1 1120/4885TTR 954/4885 |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | MMP10, MMP3, GOT2 | KDM4E 3963/4885L3MBTL1 1120/4885TTR 954/4885 |
| US-20080207569-A1 | Methods for the treatment of liver diseases | MMP1, PYGL, MMP8 | KDM4E 3780/4885L3MBTL1 2445/4885TTR 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.